Key result
Connective tissue disorders predispose to arrhythmias via myocardial fibrosis, MVP, and altered mechanotransduction.
Why the study?
Increasing evidence demonstrates that connective tissue disorders predispose to atrial and ventricular arrhythmias independent of overt cardiomyopathy or severe valvular disease, but arrhythmogenic substrates require integration.
Connective tissue disorders predispose to atrial and ventricular arrhythmias through genetic and mechanistic pathways involving fibrosis, valve geometry, and mechanotransduction, reframing them as both vascular and electrical disorders.
Answers are grounded in this paper and cite their sources.
May prompt arrhythmia vigilance in connective tissue disorders; leaves open prospective validation of mechanistic pathways.
Background Connective tissue disorders (CTDs) such as Marfan syndrome, Loeys-Dietz syndrome, and Ehlers-Danlos syndromes are traditionally defined by vascular fragility and aortic complications. Increasing evidence, however, demonstrates that CTDs also predispose to atrial and ventricular arrhythmias, often independent of overt cardiomyopathy or severe valvular disease. Content This review integrates emerging data on the arrhythmogenic substrates of CTDs. Four mechanistic bridges are emphasized: (1) diffuse myocardial fibrosis driven by dysregulated TGF-β signaling, (2) structural valve and annular abnormalities, particularly mitral valve prolapse and mitral annular disjunction, (3) altered mechanotransduction linking extracellular matrix instability to cytoskeletal and nuclear signaling pathways, and (4) downstream ion-channel and gap-junction remodeling as secondary amplifiers. We outline the genetic architecture underlying these processes, focusing on established CTD-implicated genes in the TGF-β/SMAD pathway, valve and annulus regulators, cytoskeletal and myocyte-coupling proteins, and extracellular matrix components, while incorporating emerging CTD modifiers that expand the spectrum of arrhythmia susceptibility. Summary Recognition of CTDs as both vascular and electrical disorders reframes clinical management. Imaging markers such as mitral annular disjunction and diffuse fibrosis, together with targeted ambulatory rhythm monitoring and consideration of genetic context, may improve recognition of higher-risk phenotypes. Therapeutic strategies must balance arrhythmia control with procedural risk in fragile connective tissue substrates. Conclusions By unifying genetic, mechanistic, and clinical insights, this review provides an integrated framework for understanding arrhythmias in CTDs. It underscores the need for prospective registries and genotype-phenotype studies to refine surveillance and prevention strategies.
No takes yet. Share an insight, caveat, or question.
Dreher et al. (2026) conducted a review in Connective tissue disorders and cardiac arrhythmias. Connective tissue disorders predispose patients to atrial and ventricular arrhythmias through mechanisms including diffuse myocardial fibrosis, mitral valve prolapse, and altered mechanotransduction.
Synapse has enriched 10 related papers. Consider them for comparative context: